SEC Comment Letter for Dianthus Therapeutics, (DNTH) — Jan 29, 2026
Dianthus Therapeutics, Inc. /DE/
Date: Jan. 29, 2026 · CIK: 0001690585 · Accession: 0000000000-26-001090
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293014
Letter
Re: Dianthus Therapeutics, Inc. Registration Statement on Form S-3 Filed January 28, 2026 File No. 333-293014 Dear Marino Garcia:
January 29, 2026
Marino Garcia Chief Executive Officer Dianthus Therapeutics, Inc. 7 Times Square, 43rd Floor New York, NY 10036
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Melanie E. Neary, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 29, 2026 Marino Garcia Chief Executive Officer Dianthus Therapeutics, Inc. 7 Times Square, 43rd Floor New York, NY 10036 Re: Dianthus Therapeutics, Inc. Registration Statement on Form S-3 Filed January 28, 2026 File No. 333-293014 Dear Marino Garcia: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Melanie E. Neary, Esq. </TEXT> </DOCUMENT>